Bristol Myers Squibb (BMS) is serving as the Foundational Sponsor of LungÕ 2026 – Virtual Global Congress on Lung Oncology, an international virtual medical congress taking place on November 5, 2026. The event brings together experts in thoracic oncology to discuss advances in lung cancer diagnosis, treatment, and multidisciplinary care, with an emphasis on translating scientific evidence into clinical practice.
Part of OncoDaily’s O Series, LungÕ 2026 addresses major developments in lung cancer management, including early detection, molecular diagnostics, targeted therapies, immunotherapy, treatment sequencing, and equitable access to cancer care.
Bristol Myers Squibb’s support as Foundational Sponsor contributes to an international educational initiative focused on sharing clinical knowledge and addressing challenges in lung oncology.
Bristol Myers Squibb: Supporting Progress in Oncology
Bristol Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases.
The company’s research and development activities span several therapeutic areas, including oncology, hematology, cardiovascular diseases, immunology, and neuroscience.
With a longstanding commitment to oncology research, BMS continues to pursue the development of medicines through scientific research, differentiated research platforms, and emerging technologies.
Beyond drug development, the company identifies health equity as an important priority, seeking to improve outcomes among populations disproportionately affected by serious diseases.
The independent Bristol Myers Squibb Foundation also works with communities and healthcare systems to address disparities and support sustainable improvements in health.
As Foundational Sponsor of LungÕ 2026, BMS supports a congress dedicated to discussing contemporary treatment strategies and the challenges of delivering effective lung cancer care across different healthcare settings.
LungÕ 2026: Addressing the Global Burden of Lung Cancer
Lung cancer remains the leading cause of cancer-related mortality worldwide. According to the World Health Organization, approximately 2.5 million new lung cancer cases and 1.8 million deaths were recorded globally in 2022.
In the United States, an estimated 229,410 new cases and 124,990 deaths are expected in 2026.
Despite advances in diagnosis and treatment, outcomes remain strongly influenced by the stage at which lung cancer is detected. Patients diagnosed with early-stage disease may be eligible for curative-intent treatment, while advanced-stage disease continues to present substantial clinical challenges.
Over the past decade, molecularly targeted treatments, immune checkpoint inhibitors, and biomarker-guided therapeutic strategies have changed the management of lung cancer.
These developments have expanded treatment options for selected patients with non-small cell lung cancer (NSCLC), while advances in immunotherapy have also influenced the treatment of small cell lung cancer (SCLC).
LungÕ 2026 provides an international forum for examining these developments and discussing how they can be incorporated into routine clinical decision-making.
From Molecular Diagnostics to Multidisciplinary Treatment
The scientific program of LungÕ 2026 covers the full clinical spectrum of lung cancer, from early-stage disease to locally advanced and metastatic settings.
A central focus is the growing importance of precision diagnostics and biomarker-driven treatment selection. Sessions explore how molecular testing can inform therapeutic decisions and help clinicians identify appropriate treatment strategies.
The congress also examines the evolving roles of targeted therapies and immunotherapy, including treatment sequencing, resistance mechanisms, and individualized management.
Multidisciplinary care represents another major theme, reflecting the importance of collaboration among medical oncologists, radiation oncologists, surgeons, pathologists, and other healthcare professionals.
Alongside scientific developments, the program addresses disparities in access to diagnosis and treatment, recognizing that improvements in cancer outcomes depend not only on therapeutic innovation but also on the ability to deliver appropriate care to patients.
International Scientific Leadership
The congress is guided by two specialists from the Sylvester Comprehensive Cancer Center at the University of Miami.
Gilberto Lopes, Chief of the Division of Medical Oncology at the University of Miami and Associate Director of Sylvester Comprehensive Cancer Center, serves in the scientific leadership of LungÕ 2026. He was the principal investigator of the KEYNOTE-42 trial, which investigated pembrolizumab in advanced non-small cell lung cancer.
Estelamari Rodriguez, a triple board-certified hematologist and medical oncologist at Sylvester Comprehensive Cancer Center, also contributes to the congress’s scientific leadership. Her areas of expertise include thoracic oncology, lung cancer, and cancer disparities.
Their involvement reflects the congress’s emphasis on evidence-based clinical practice, multidisciplinary collaboration, and addressing differences in cancer outcomes.
Advancing Lung Cancer Care Through International Collaboration
LungÕ 2026 brings together international oncology professionals to examine how current scientific knowledge can guide treatment decisions across different stages of lung cancer.
The congress emphasizes the practical application of clinical evidence, including selecting appropriate therapies, managing resistance, refining treatment sequences, and strengthening patient-centered care.
With Bristol Myers Squibb as Foundational Sponsor, the event highlights the role of collaboration between the oncology community and the biopharmaceutical sector in supporting medical education and scientific exchange.
As lung cancer treatment continues to evolve, international educational initiatives such as LungÕ 2026 provide opportunities for clinicians to discuss emerging evidence, share clinical perspectives, and address challenges that remain in everyday oncology practice.
LungÕ 2026 – Virtual Global Congress on Lung Oncology takes place virtually on November 5, 2026, as part of OncoDaily’s O Series. The congress is accessible through the OncoDaily event platform, with sign-in required to watch the live stream.
